Provided by Tiger Trade Technology Pte. Ltd.

INDIVIOR PLC

35.69
+1.343.90%
Post-market: 35.690.00000.00%19:49 EDT
Volume:2.69M
Turnover:95.67M
Market Cap:4.21B
PE:12.90
High:35.90
Open:34.76
Low:34.47
Close:34.35
52wk High:42.81
52wk Low:22.22
Shares:118.00M
Float Shares:116.45M
Volume Ratio:1.27
T/O Rate:2.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):1.64
ROE:12.20%
ROA:26.40%
PB:-20.25
PE(LYR):21.76

Loading ...

Supernus, Indivior Agree All-Stock Merger, Combined Firm to Trade as Supernus on NASDAQ

Reuters
·
Aug 03

Supernus Pharmaceuticals - Stockholders Will GET 1.5401 Common Shares of Indivior Pharmaceuticals for Each Share of Supernus Pharmaceuticals They Own

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Inc: Indivior Pharmaceuticals Stockholders Will Own Approximately 56.5% of Combined Company

THOMSON REUTERS
·
Aug 03

Supernus: Combined Co Expected to Benefit from Immediate Scale and $125 Mln of Expected Annual Cost Synergies

THOMSON REUTERS
·
Aug 03

Supernus: Indivior Pharmaceuticals Stockholders to GET One-Time Special Cash Dividend of $1 Bln in Aggregate Immediately Prior to Closing of Merger

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Inc - Definitive Agreement to Combine in a Tax-Free All-Stock Merger

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Inc - Combined Entity to be Named Supernus, Inc. and Jack Khattar to Serve as President and Chief Executive Officer

THOMSON REUTERS
·
Aug 03

Earning Preview: INDIVIOR PLC Q2 revenue is expected to increase by 25.79%, and institutional views are bullish

Earnings Agent
·
Jul 29

Indivior to Report Q2 2026 Results, Host Webcast Presentation

Reuters
·
Jul 23

Rxsight Names Aziz Mottiwala CEO, Ron Kurtz to Become Chief Medical Officer

Reuters
·
Jul 16

Indivior CSO Christian Heidbreder Disposes of $764,432.04 in Common Shares

Reuters
·
Jul 14

Indivior Pharmaceuticals (INDV) Pushes Cost Cuts And Growth, Is It Still 17% Undervalued?

Simply Wall St.
·
Jun 26

Indivior Pharmaceuticals Initiated at Overweight by Barclays

Dow Jones
·
Jun 18

Indivior Pharmaceuticals, Inc :  Barclays Initiates Coverage With Overweight Rating and Target Price $46

THOMSON REUTERS
·
Jun 18

Barclays Initiates Indivior at Overweight With $46 Price Target

MT Newswires Live
·
Jun 18

Indivior initiated with an Overweight at Barclays

TIPRANKS
·
Jun 18

U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis

Reuters
·
Jun 18

REFILE-FACTBOX-UK Market Exodus: Companies that moved away from London listing in recent years

Reuters
·
Jun 16

Indivior Chief Scientific Officer Christian Heidbreder disposes of 18,586 shares for $707,779.16

Reuters
·
Jun 13

UK Market Exodus: Companies that moved away from London listing in recent years

Reuters
·
Jun 12